Dasatinib (BMS-354825) has increased activity against Bcr-Abl compared to imatinib in primary CML cells in vitro, but does not eradicate quiescent CML stem cells

Copland, M. , Hamilton, A., Baird, J., Barow, M., Allan, E., Elrick, L. and Holyoake, T. (2005) Dasatinib (BMS-354825) has increased activity against Bcr-Abl compared to imatinib in primary CML cells in vitro, but does not eradicate quiescent CML stem cells. Blood, 106(11), 205A-205A.

Full text not currently available from Enlighten.


Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Copland, Professor Mhairi
Authors: Copland, M., Hamilton, A., Baird, J., Barow, M., Allan, E., Elrick, L., and Holyoake, T.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Blood

University Staff: Request a correction | Enlighten Editors: Update this record